How do you approach treatment in premenopausal patients who develop a contralateral HR+ breast cancer while already on tamoxifen and ovarian function suppression?
How would you manage endocrine therapy 7 years after the original ER+/PR+/HER2- IDC, while on adjuvant tamoxifen/OFS develops a contralateral ER+/PR+/HER2- cT1c multifocal ILC?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
Several pieces of information are lacking in this clinical case to make a solid treatment recommendation: what is the current age of the patient? What is her menopausal status? Is the new contralateral breast cancer clinically node negative?
Since this new second primary contralateral breast cancer ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on
If she doesn't need adjuvant chemo after surgery, I would switch her to OFS+AI for at least 5 years.
Join for free or sign in to see the full answer